Report
Hugo Solvet

GENMAB: Data-Driven Medicine is getting more traction | BUY | DKK1450(+4%)

GENMAB - BUY | DKK1450(+4%)
Data-Driven Medicine is getting more traction

Agreement to identify new disease targets/biomarkers
DDM getting more traction among the pharma/biotech industry
Recipe for success: network is a key
Underlying
Genmab A/S

Genmab is a biotechnology company specializing in the creation and development of differentiated human antibody therapeutics focused on the treatment of cancer. Co.'s product pipeline includes one marketed product, Arzerra, daratumumab in late stage clinical development, four antibodies in clinical development, and over 20 in-house and partnered pre-clinical programs. Co.'s Arzerra (ofatumumab) is a human monoclonal antibody which targets an epitope on the CD20 molecule. Co.'s proprietary technologies include the DuoBody technology, which creates antibodies that can target two molecules at once, and the HexaBody technology, which allows for the creation of more potent antibodies.

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Hugo Solvet

Other Reports on these Companies
Other Reports from Bryan Garnier
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch